Arbitrage Microfluidic Manufacturing via Chinese Foundry Spread
- Organization
- NSF SBIR program funding R&D with manufacturing cost targets but no international supply chain infrastructure
- Sector
- DELEON TECHNOLOGIES needing scaled manufacturing demonstrations for Phase II SBIR funding
- Location
- Location unspecified
Source reference
Executive summary
Current state
NSF awarded DELEON TECHNOLOGIES $305K SBIR Phase I funding to develop a disposable microfluidic chip for urine analysis, creating a classic "SBIR Valley of Death" scenario where government-funded technical capability exists without commercial infrastructure for FDA clearance, manufacturing scale, or data monetization.
Market catalyst
DELEON has $2/chip manufacturing target but lacks international supply chain relationships and manufacturing scale expertise, creating a 60-75% cost arbitrage opportunity between their budget and actual Chinese microfluidic foundry pricing
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.